Old and new anti-obesity drugs

被引：0
|
作者：
Dodangeh, Salimeh [1 ]
Hasani-Ranjbar, Shirin [2 ]
机构：
[1] Univ Tehran Med Sci, Endocrinol & Metab Clin Sci Inst, Endocrinol & Metab Res Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Endocrinol & Metab Clin Sci Inst, Obes & Eating Habits Res Ctr, Tehran, Iran
来源：
JOURNAL OF DIABETES AND METABOLIC DISORDERS | 2024年 / 24卷 / 01期
关键词：
Obesity; Overweight; Anti-obesity medication; Weight loss medication; GLUCAGON-LIKE PEPTIDE-1; GLP-1 RECEPTOR AGONIST; WEIGHT-LOSS; CLINICAL ENDOCRINOLOGISTS; APPETITE SUPPRESSION; AMERICAN ASSOCIATION; EXTENDED-RELEASE; GENE-EXPRESSION; OBESE-PATIENTS; DOUBLE-BLIND;
D O I：
10.1007/s40200-024-01512-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Obesity is a pandemic problem that correlates with a cluster of metabolic factors leading to poor cardiovascular outcomes, morbidity, and an increased risk of overall mortality. It is necessary to approach obesity with a comprehensive treatment plan, which may involve lifestyle modifications (diet, exercise, and behavioral therapy) and pharmacological interventions. This article provides an overview of the mechanisms of action, efficacy, and safety of available long-term anti-obesity drugs and introduces other potential agents under investigation.
引用
收藏
页数：13
相关论文
共 50 条
  • [31] Anti-obesity drugs and neural circuits of feeding
    Adan, Roger A. H.
    Vanderschuren, Louk J. M. J.
    la Fleur, Susanne E.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (04) : 208 - 217
  • [32] Anti-obesity drugs: The present and future perspectives
    Lassen, Pierre Bel
    Aron-Wisnewsky, Judith
    CAHIERS DE NUTRITION ET DE DIETETIQUE, 2023, 58 (04): : 273 - 282
  • [33] A short history of serotonergic anti-obesity drugs
    Heal, D. J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 127 - 127
  • [34] Do we need anti-obesity drugs?
    Hainer, Vojtech
    Hainerova, Irena Aldhoon
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 : 8 - 20
  • [35] HOW DO ANTI-OBESITY DRUGS WORK
    TURNER, P
    INTERNATIONAL JOURNAL OF OBESITY, 1978, 2 (03) : 343 - 348
  • [36] Who should pay for anti-obesity drugs?
    Sharma, AM
    NATIONAL MEDICAL JOURNAL OF INDIA, 1999, 12 (02): : 79 - 79
  • [37] Anti-obesity drugs and valvular heart disease
    不详
    DIABETES OBESITY & METABOLISM, 1999, 1 (04): : 255 - 255
  • [38] Anti-obesity drugs: past, present and future
    Rodgers, R. John
    Tschoep, Matthias H.
    Wilding, John P. H.
    DISEASE MODELS & MECHANISMS, 2012, 5 (05) : 621 - 626
  • [39] Serotonergic targets for novel anti-obesity drugs
    Simansky, K. J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 127 - 127
  • [40] The obesity pipeline: current strategies in the development of anti-obesity drugs
    Dunstan Cooke
    Steve Bloom
    Nature Reviews Drug Discovery, 2006, 5 : 919 - 931
12345